FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999694614> ?p ?o ?g. }

• W2999694614 abstract "ABSTRACT Giant cell tumor of bone (GCTB) is an aggressive osteolytic tumor that causes substantial morbidity. We present data from a second open label phase 2 study of denosumab in GCTB. Patients (pts) with surgically unresectable GCTB (Cohort 1), resectable GCTB with planned surgery (Cohort 2), and pts who transferred from the first phase 2 study (Cohort 3) received SC denosumab (120 mg, Q4W), with additional doses on days 8 and 15 (Cohorts 1–2). Prespecified efficacy and safety analyses included all pts who received denosumab. Radiographic assessments of tumor response included pts with ≥1 evaluable time point response (TPR); assessments included RECIST (lesion size), EORTC (PET Standardized Uptake Value by Body Weight [SUVbw]), and Density/Size (CT Hounsfield units). Pts (N = 282) were 58% women, mean age 36 (SD 13) years; 46% had recurrent unresectable disease. AEs were reported in 236 pts (84%); most frequent were arthralgia 20%; headache 18%; nausea 17%; fatigue 16%; back pain 15%; and extremity pain 15%. Osteonecrosis of the jaw was reported in 3 pts (1%). One pt died of respiratory failure, not denosumab-related. Hypocalcemia was reported in 15 pts (5%): 14, grade 1 or 2; 1, grade 3 not deemed clinically significant by the investigator. Of 100 pts in Cohort 2, 90% had no surgery or less morbid surgery than planned. Radiologic analyses included 190 pts. An objective complete or partial tumor response was observed in 72% of pts based on best response, any criteria. Of pts with ≥1 objective tumor response, response rates were 25% with RECIST, 96% with EORTC, and 76% with Density/Size criteria. Among pts with ≥1 evaluable TPR, the median time to objective tumor response was 3.1 months (95% CI 2.89, 3.65) based on best response using any tumor response criteria. Among pts with ≥2 evaluable TPRs ≥12 weeks apart, 96% had tumor control sustained ≥12 weeks based on the best response using any tumor response criteria. Eleven pts (6%) had disease progression. Conclusion: Denosumab appeared to be well tolerated in pts with GCTB, reduced requirements for morbid surgery, and provided a durable objective radiologic response for the majority of pts. Denosumab continues to be studied as a potential treatment for GCTB. Disclosure J. Blay: JY Blay has served as an advisory board member for Novartis, GSK, Roche, MSD, and Pharmamar. He has conducted corporate-funded research for Novartis, GSK, Roche, MSD, and Pharmamar. S. Chawla: Sant Chawla has been an advisory board member for and has received corporate-sponsored research funding from Amgen, Threshold, Cytrax, Glaxxo, and Berg Pharma. E. Choy: E. Choy has served as an advisory board member for Amgen, Sanofi-Aventis, and Biomed Valley Discoveries. S. Ferrari: S. Ferrari has received funds from: AMGEN, MOLMED, PharmaMar, and Pfizer. He received funds for participation to scientific meetings from Takeda. P. Reichardt: P. Reichardt has received honoraria for lectures from Amgen Inc. P. Rutkowski: P. Rutkowski has served as an advisory board member for Norvartis, BMS, and MSD. He has also received honoraria for lectures and travel grants from Novartis, Pfizer, Roche, BMS, and MSD. D. Thomas: David Thomas conducts corporate-sponsored research with Pfizer and AMGEN. Y. Qian: Y. Qian is an employee and stockholder of Amgen Inc. I. Jacobs: I. Jacobs is an employee and stockholder of Amgen Inc. All other authors have declared no conflicts of interest." @default.
• W2999694614 created "2020-01-23" @default.
• W2999694614 creator A5018551530 @default.
• W2999694614 creator A5048170384 @default.
• W2999694614 creator A5051031495 @default.
• W2999694614 creator A5057483557 @default.
• W2999694614 creator A5058372546 @default.
• W2999694614 creator A5063245135 @default.
• W2999694614 creator A5068746768 @default.
• W2999694614 creator A5071532449 @default.
• W2999694614 creator A5073906112 @default.
• W2999694614 creator A5076690638 @default.
• W2999694614 date "2012-09-01" @default.
• W2999694614 modified "2023-10-11" @default.
• W2999694614 title "Efficacy and Safety of Denosumab in Giant Cell Tumor of Bone: Updated Results with Independent Radiographic Assessment of Response" @default.
• W2999694614 doi "https://doi.org/10.1016/s0923-7534(20)34053-9" @default.
• W2999694614 hasPublicationYear "2012" @default.
• W2999694614 type Work @default.
• W2999694614 sameAs 2999694614 @default.
• W2999694614 citedByCount "0" @default.
• W2999694614 crossrefType "journal-article" @default.
• W2999694614 hasAuthorship W2999694614A5018551530 @default.
• W2999694614 hasAuthorship W2999694614A5048170384 @default.
• W2999694614 hasAuthorship W2999694614A5051031495 @default.
• W2999694614 hasAuthorship W2999694614A5057483557 @default.
• W2999694614 hasAuthorship W2999694614A5058372546 @default.
• W2999694614 hasAuthorship W2999694614A5063245135 @default.
• W2999694614 hasAuthorship W2999694614A5068746768 @default.
• W2999694614 hasAuthorship W2999694614A5071532449 @default.
• W2999694614 hasAuthorship W2999694614A5073906112 @default.
• W2999694614 hasAuthorship W2999694614A5076690638 @default.
• W2999694614 hasBestOaLocation W29996946141 @default.
• W2999694614 hasConcept C126322002 @default.
• W2999694614 hasConcept C141071460 @default.
• W2999694614 hasConcept C2776286101 @default.
• W2999694614 hasConcept C2776541429 @default.
• W2999694614 hasConcept C2780580376 @default.
• W2999694614 hasConcept C71924100 @default.
• W2999694614 hasConcept C72563966 @default.
• W2999694614 hasConceptScore W2999694614C126322002 @default.
• W2999694614 hasConceptScore W2999694614C141071460 @default.
• W2999694614 hasConceptScore W2999694614C2776286101 @default.
• W2999694614 hasConceptScore W2999694614C2776541429 @default.
• W2999694614 hasConceptScore W2999694614C2780580376 @default.
• W2999694614 hasConceptScore W2999694614C71924100 @default.
• W2999694614 hasConceptScore W2999694614C72563966 @default.
• W2999694614 hasLocation W29996946141 @default.
• W2999694614 hasOpenAccess W2999694614 @default.
• W2999694614 hasPrimaryLocation W29996946141 @default.
• W2999694614 hasRelatedWork W2030089772 @default.
• W2999694614 hasRelatedWork W2081369132 @default.
• W2999694614 hasRelatedWork W2340269762 @default.
• W2999694614 hasRelatedWork W2528151402 @default.
• W2999694614 hasRelatedWork W2560127142 @default.
• W2999694614 hasRelatedWork W2606074403 @default.
• W2999694614 hasRelatedWork W2907417639 @default.
• W2999694614 hasRelatedWork W2909099970 @default.
• W2999694614 hasRelatedWork W2922547188 @default.
• W2999694614 hasRelatedWork W2965424548 @default.
• W2999694614 hasRelatedWork W2977583846 @default.
• W2999694614 hasRelatedWork W2979367976 @default.
• W2999694614 hasRelatedWork W2981063766 @default.
• W2999694614 hasRelatedWork W2998930136 @default.
• W2999694614 hasRelatedWork W2999153110 @default.
• W2999694614 hasRelatedWork W2999335024 @default.
• W2999694614 hasRelatedWork W2999399846 @default.
• W2999694614 hasRelatedWork W2999710896 @default.
• W2999694614 hasRelatedWork W2999805559 @default.
• W2999694614 hasRelatedWork W3000278797 @default.
• W2999694614 isParatext "false" @default.
• W2999694614 isRetracted "false" @default.
• W2999694614 magId "2999694614" @default.
• W2999694614 workType "article" @default.